FDA Rips Aegerion Exec For Drug Promo Claims On CNBC
By Jeff Overley (November 12, 2013, 6:40 PM EST) -- The U.S. Food and Drug Administration on Friday torched the CEO of Aegerion Pharmaceuticals Inc. for comments made on CNBC, saying viewers were left with the faulty impression that cholesterol drug Juxtapid isn't risky and by itself can ensure they live long enough to "meet their grandkids."
According to an FDA warning letter, CEO Marc Beer twice was a guest this year on the financial news network's show "Fast Money," and made a number of unsubstantiated and misleading remarks about the orphan drug's safety and effectiveness.
In June, for example, Beer discussed Juxtapid's target disease — a genetic condition known as...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!